Strong Industry Presence Andelyn Biosciences operates within the rapidly expanding biotechnology and gene therapy sectors, demonstrating a solid revenue base of up to $250 million and a robust pipeline of over 75 clinical trials, positioning it as a key partner for innovative biotech solutions.

Strategic Collaborations Recent partnerships with Tern Therapeutics, Amplo Biotechnology, and Grace Science showcase a focus on late-stage process qualification and niche gene therapies, opening opportunities for integrated supply chain support and advanced manufacturing services.

Advanced Manufacturing Capabilities With a state-of-the-art 180,000 square-foot facility and expertise in viral vectors, GMP plasmids, and suspension platform production, Andelyn offers scalable solutions suitable for both clinical and commercial demands, ideal for customers seeking reliable GMP manufacturing partners.

Focused Innovation The company's commitment to expanding its AAV platform through licensing agreements and technology transfer, including MyoAAV plasmids, indicates ongoing innovation that can attract clients developing cutting-edge gene therapies requiring customized vector solutions.

Market Leadership As a pioneer with extensive experience in viral vector and vaccine manufacturing, Andelyn’s proven track record of over 2,000 research and clinical batches presents a compelling value proposition for biotech companies needing trusted manufacturing excellence to accelerate their product development.